ArticlePloS one2018

Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.

Jeffrey W Craig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.